The autism therapy industry has become an increasingly prominent target for government enforcement action at both federal and state levels.
Applied Behavior Analysis therapy, currently the dominant form of autism treatment in the United States, carries all the hallmarks that typically attract healthcare fraud investigators.
Explosive reimbursement growth, low barriers to entry, and thin oversight have combined to draw a wave of HHS-OIG audits, False Claims Act settlements, and criminal prosecutions.
On August 5, the Centers for Medicare and Medicaid Services released a 173-page State Medicaid and Children’s Health Insurance Program Applied Behavior Analysis Toolkit to help states tighten billing oversight.
The comprehensive guide targets precisely the billing practices that federal investigators have increasingly focused on in recent enforcement actions across the sector.
Medicaid and Children’s Health Insurance Program spending on ABA increased 421% between 2021 and 2025, far outpacing growth in the number of children with an autism diagnosis receiving services.
Direct Medicaid payments to ABA providers grew from $660 million in 2019 to $2.2 billion in 2023, making ABA the fastest-growing service line in the entire Medicaid program.
CMS has been explicit that the toolkit does not create new federal requirements, does not reduce coverage obligations, and does not endorse a single treatment model.
Congress has also entered the picture, with the House Committee on Education and Workforce opening its own inquiry into the sector in July.
The committee sent a letter to Simcha Bendet, founder of autism therapy provider The Perfect Child, LLC, demanding billing and reimbursement records going back to 2020.
That inquiry followed a Wall Street Journal report detailing alleged overbilling and aggressive collection practices connected to the provider.
The congressional oversight is premised on protecting ERISA-governed and employer-sponsored health plans from abuse, raising issues similar to earlier Medicaid-focused OIG and DOJ activity.
Collectively, the CMS toolkit, OIG audit series, recent DOJ activity, and congressional investigations all point toward significantly heightened scrutiny of ABA billing practices across the industry.
Investigators are focusing on documentation that fails to individualise treatment, treatment plans defaulting to maximum allowable hours, and billing structures that obscure actual time spent with patients.
Referral arrangements with financial strings attached have also emerged as a key area of concern for both federal and congressional investigators examining the sector.
Providers are being urged to proactively review their processes and update compliance protocols before enforcement attention broadens beyond the most egregious cases.